Abiraterone (zytiga), a novel agent for the management of castration-resistant prostate cancer.

@article{Goldberg2013AbirateroneA,
  title={Abiraterone (zytiga), a novel agent for the management of castration-resistant prostate cancer.},
  author={Tamara B L Goldberg and Evangelina Berrios-Colon},
  journal={P & T : a peer-reviewed journal for formulary management},
  year={2013},
  volume={38 1},
  pages={
          23-6
        }
}
INTRODUCTION Prostate cancer is the second most common cancer diagnosed in men living in the U.S. The disease was expected to account for more than 28,000 deaths in 2012,1 and more than 241,700 new cases were expected to be diagnosed that year.2 Prostate cancer usually affects men after the age of 40. Besides age, other risk factors include ethnicity, dietary practices, and genetic predisposition.3 The highest incidence is seen in African-American patients, followed by Caucasian and Hispanic… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 18 references

National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Prostate cancer

JL Mohler, AJ Armstrong, RR Bahnson
Available at: www.nccn. org/professionals/physician_gls/pdf/ prostate.pdf. Accessed June • 2012

eds.). SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations)

N Howlader, AM Noone, M Krapcho
National Cancer Institute. Based on November 2011 SEER data submission. Updated August 20, • 2012

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2008